Author: Daniel Tillett

27 October 2021 – Race Oncology Limited (“Race”) is pleased to announce it has entered into a research collaboration with Dr Dan Dominissini of the Chaim Sheba Medical Center, Israel to analyse clinical patient samples from the ongoing Zantrene® Phase…

United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF 19 October 2021 – Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US…

Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US 11,135,201) from the United States Patent and Trademarks Office (USPTO) for its cancer drug, Zantrene® (bisantrene dihydrochloride). This is Race’s fifth patent granted for…

Zantrene at low concentrations kills high FTO producing melanoma cancer cells Sensitivity to Zantrene correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells Results are highly supportive of future…

09 August 2021 – Race Oncology Limited (“Race”) is pleased to announce that the first patient has been dosed in the Phase 1b/2 trial in relapsed/refractory Acute Myeloid Leukaemia (ASX Announcement: 22 June 2021). This investigator-led trial supervised by Professor…

22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed an agreement with The Sheba Fund for Health Services and Research, Chaim Sheba Medical Center to commence a Phase 1b/2 trial in relapsed/refractory Acute Myeloid…

Race Oncology’s Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED) presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th June 2021.

Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in Israel Trialog Clinical Trials Ltd to supply trial drugs and provide other clinical services Clinical trial contract is in final…

Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our Three Pillar strategy to commercialise Bisantrene.

Contract Research Organisation Parexel has been appointed to support an Australian trial of Bisantrene in Acute Myeloid Leukemia (AML) patients with extramedullary disease The study led by Associate Professor Anoop Enjeti will underpin future Phase 2/3 trials in the USA…